OncRef

Clinical Trial: NCT04128501

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:M.D. Anderson Cancer Center
Information Provided By:M.D. Anderson Cancer Center
Last Update Posted:2026-10-05

Study Overview

Brief Summary

This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.

Official Title

A Phase II Study of Venetoclax in Combination With Azacitidine in the Post-Transplant Setting for AML, T Cell Leukemia, and Mixed Phenotype Acute Leukemia

Conditions

Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia

Intervention / Treatment

  • Drug: Azacitidine
  • Drug: Venetoclax

Other Study ID Numbers

  • 2019-0353
  • NCI-2019-06674
  • 2019-0353

Start Date (Actual)

2020-05-05

Primary Completion Date (Estimated)

2026-12-31

Study Completion Date (Estimated)

2026-12-31

Enrollment (Actual)

100

Study Type

Interventional

Phase

Phase 2